However, with the progression of obesity, prolonged and excessive increase of A-FABP may exacerbate metabolic and cardiovascular disorders through its effects on non-adipose tissues, including macrophages, endothelium, cardiomyocytes and hepatocytes. Here, FABP4 is linked to obesity disorder.